Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: A two-stage longitudinal clinical study

Journal of Clinical Oncology

Volumn 31, Issue 29, 2013, Pages 3647-3655

  Yin, Jianhua ^a   Li, Nan ^a   Han, Yifang ^a   Xue, Jie ^a   Deng, Yang ^a   Shi, Jie ^a   Guo, Weixing ^a   Zhang, Hongwei ^a   Wang, Hongyang ^a   Cheng, Shuqun ^a   Cao, Guangwen ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; LAMIVUDINE; ANTIVIRUS AGENT; NUCLEOSIDE; NUCLEOTIDE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER RESECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; VIRUS LOAD; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; HEPATITIS B, CHRONIC; LIVER NEOPLASMS; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; VIROLOGY;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATECTOMY; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; LONGITUDINAL STUDIES; NUCLEOSIDES; NUCLEOTIDES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84890963473     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.48.5896     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011
2. Poon RT, Fan ST, Lo CM, et al: Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol 18:1094-1101, 2000
3. Llovet JM, Schwartz M, Mazzaferro V: Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 25:181-200, 2005
4. Chen L, Zhang Q, Chang W, et al: Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. Eur J Cancer 48:1977-1987, 2012
5. Hung IF, Poon RT, Lai CL, et al: Recurrence of hepatitis B related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol 103:1663-1673, 2008
6. Wu JC, Huang YH, Chau GY, et al: Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 51: 890-897, 2009
7. Yeh CT, So M, Ng J, et al: Hepatitis B virus-DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma. Hepatology 52:1922-1933, 2010
8. An HJ, Jang JW, Bae SH, et al: Sustained low hepatitis B viral load predicts good outcome after curative resection in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 25:1876-1882, 2010
9. Huang G, Lai EC, Lau WY, et al: Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels. Ann Surg 257:490-505, 2013
10. Du Y, Su T, Ding Y, et al: Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation. Hepat Mon 12:e6031, 2012
11. Manns MP, McHutchison JG, Gordon SC, et al: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358:958-965, 2001
12. Wai CT, Chu CJ, Hussain M, et al: HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 36:1425-1430, 2002
13. Yang HI, Yeh SH, Chen PJ, et al: Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 100:1134-1143, 2008
14. Chan AC, Chok KS, Yuen WK, et al: Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg 146:675-681, 2011
15. Chuma M, Hige S, Kamiyama T, et al: The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol 44:991-999, 2009
16. Huang G, Yang Y, Shen F, et al: Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load. Ann Surg Oncol 20:1482-1490, 2013
17. Wu CY, Chen YJ, Ho HJ, et al: Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 308:1906-1914, 2012
18. Lok AS: Does antiviral therapy prevent recurrence of hepatitis B virus-related hepatocellular carcinoma after curative liver resection? JAMA 308: 1922-1924, 2012
19. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 42:1208-1236, 2005
20. Yin J, Xie J, Liu S, et al: Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma. Am J Gastroenterol 106:81-92, 2011
21. Yin J, Zhang H, Li C, et al: Role of hepatitis B virus genotype mixture, subgenotypes C2 and B2 on hepatocellular carcinoma: Compared with chronic hepatitis B and asymptomatic carrier state in the same area. Carcinogenesis 29:1685-1691, 2008
22. Ma NF, Lau SH, Hu L, et al: COOH-terminal truncated HBV X protein plays key role in hepatocarcinogenesis. Clin Cancer Res 14:5061-5068, 2008
23. Huang Y, Wang Z, An S, et al: Role of hepatitis B virus genotypes and quantitative HBV DNA in metastasis and recurrence of hepatocellular carcinoma. J Med Virol 80:591-597, 2008
24. Huang Y, Tong S, Tai AW, et al: Hepatitis B virus core promoter mutations contribute to hepatocarcinogenesis by deregulating SKP2 and its target, p21. Gastroenterology 141:1412-1421, 2011
25. Mun HS, Lee SA, Kim H, et al: Novel F141L pre-S2 mutation in hepatitis B virus increases the risk of hepatocellular carcinoma in patients with chronic genotype C infections. J Virol 85:123-132, 2011
26. Lara-Pezzi E, Gómez-Gaviro MV, Gálvez BG, et al: The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression. J Clin Invest 110:1831-1838, 2002
27. Ou DP, Tao YM, Tang FQ, et al: The hepatitis B virus X protein promotes hepatocellular carcinoma metastasis by upregulation of matrix metalloproteinases. Int J Cancer 120:1208-1214, 2007
28. Liu H, Xu L, He H, et al: Hepatitis B virus X protein promotes hepatoma cell invasion and metastasis by stabilizing Snail protein. Cancer Sci 103: 2072-2081, 2012
29. Cheng AS, Wong N, Tse AM, et al: RNA interference targeting HBx suppresses tumor growth and enhances cisplatin chemosensitivity in human hepatocellular carcinoma. Cancer Lett 253: 43-52, 2007
30. Peng CY, Chien RN, Liaw YF: Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy. J Hepatol 57:442-450, 2012
31. Li N, Lai EC, Shi J, et al: A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann Surg Oncol 17:179-185, 2010
32. Huang L, Li J, Lau WY, et al: Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma. J Gastroenterol Hepatol 27: 158-164, 2012
33. Lok AS, McMahon BJ: Chronic hepatitis B: Update 2009. Hepatology 50:661-662, 2009
34. Wang Y, Lau SH, Sham JS, et al: Characterization of HBV integrants in 14 hepatocellular carcinomas: Association of truncated X gene and hepatocellular carcinogenesis. Oncogene 23:142-148, 2004
35. Sze KM, Chu GK, Lee JM, et al: C-terminal truncated hepatitis B virus x protein is associated with metastasis and enhances invasiveness by CJun/matrix metalloproteinase protein 10 activation in hepatocellular carcinoma. Hepatology 57:131-139, 2013
36. Tranchart H, Chirica M, Sepulveda A, et al: Long-term outcomes following aggressive management of recurrent hepatocellular carcinoma after upfront liver resection. World J Surg 36:2684-2691, 2012
37. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer: EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol 56:908-943, 2012
38. Bruix J, Sherman M; American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: An update. Hepatology 53: 1020-1022, 2011
39. Poon D, Anderson BO, Chen LT, et al: Management of hepatocellular carcinoma in Asia: Consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 10:1111-1118, 2009